ライフサイエンスコーパス: crossover trial

1 t and 435 assigned placebo, including 101 in crossover trials).

2 ner-blinded, randomized, placebo-controlled, crossover trial.

3 year, community-based, randomized controlled crossover trial.

4 double-blind, placebo-controlled, two-period crossover trial.

5 A randomised double blind crossover trial.

6 1 hour in a randomized, double-blind, 3-way crossover trial.

7 nd, placebo-controlled, response-conditional crossover trial.

8 d, double-blind, placebo-controlled, partial crossover trial.

9 placebo-controlled, double-blind, randomized crossover trial.

10 n coinfected persons in a placebo-controlled crossover trial.

11 domized, double-blinded, placebo-controlled, crossover trial.

12 were enrolled in a randomized, prospective, crossover trial.

13 r placebo for 1 month each in a double-blind crossover trial.

14 o a hospital research unit for 24 hours in a crossover trial.

15 rolled in a double-blind, placebo-controlled crossover trial.

16 ing was assessed in a double-blind, 3-period crossover trial.

17 and 60% oxygen/40% nitrogen in a randomized, crossover trial.

18 olled in a double-blind, placebo-controlled, crossover trial.

19 o 56 years, were enrolled in a double-blind, crossover trial.

20 andomized, double-blind, placebo-controlled, crossover trial.

21 randomised double-blind, placebo-controlled crossover trial.

22 andomized to each of three pacing modes in a crossover trial.

23 ulticenter, double-blind, placebo-controlled crossover trial.

24 We did a randomised, double-blind, crossover trial.

25 acebo in a 6-week, randomized, double blind, crossover trial.

26 ets (50% of dietary energy) in a randomized, crossover trial.

27 ubjects with stable angina in a double-blind crossover trial.

28 d and 18 (81.8%) completed the double-blind, crossover trial.

29 s) in an open-label, multicenter, randomized crossover trial.

30 ot using HRT, participated in a double-blind crossover trial.

31 the alternative medications, as occurs in a crossover trial.

32 ng in an acute randomized three-intervention crossover trial.

33 DM): a multicentre, double-blind, randomised crossover trial.

34 nd, randomized, placebo-controlled, clinical crossover trial.

35 andomized, placebo-controlled, double-blind, crossover trial.

36 ted to a randomized, single-blind two period crossover trial.

37 s participated in this randomized controlled crossover trial.

38 n was a single-centre, 12-month double-blind crossover trial.

39 a single-blinded, placebo-controlled, 2 x 2 crossover trial.

40 andomized, double-masked, placebo-controlled crossover trial.

41 ults in a 2x4-week double-blind, randomised, crossover trial.

42 in a postprandial randomised, double blind, crossover trial.

43 randomized, placebo-controlled, double-blind crossover trial.

44 n was a randomized, double-blind, controlled crossover trial.

45 signed in a double blind placebo-controlled, crossover trial.

46 andomized, double-blind, placebo-controlled, crossover trial.

47 lthy volunteers in a randomized, controlled, crossover trial.

48 h elevated depressive affect in a randomized crossover trial.

49 randomized double-blind, placebo-controlled, crossover trial.

50 In this multicenter cluster-randomized crossover trial, 10 French ICUs were randomly assigned (

51 In this multicenter, cluster-randomized crossover trial, 10 French ICUs were randomly assigned (

52 tes during exercise recovery in young men.In crossover trials, 10 resistance-trained men [aged 21 +/-

53 In the randomized crossover trial, 12 volunteers successively consumed 2 d

54 In a double-blind randomized four-leg crossover trial, 14 individuals wore a removable applian

55 mmatory responses.In a randomized controlled crossover trial, 17 participants [body mass index (in kg

56 In a randomized, balanced, crossover trial, 18 healthy male participants consumed t

57 In a randomized, placebo-controlled crossover trial, 19 ragweed allergen-sensitive subjects

58 In this blinded, placebo-controlled crossover trial, 20 patients with TRD were randomly assi

59 In a multicenter randomized crossover trial, 21 patients with type 2 diabetes (age 5

60 multicenter, randomized, single-blind, 2-arm crossover trial, 240 patients underwent 2 single photon

61 label, multinational, two-center, randomized crossover trial, 26 adults with type 2 diabetes requirin

62 In a randomized, single-blinded, controlled, crossover trial, 28 healthy adults (mean +/- standard de

63 In a single-site crossover trial, 30 adult patients with classical PKU di

64 ed, double-blind, placebo-controlled, 3-week crossover trial, 34 patients with primary polydipsia rec

65 nter, randomized, placebo (PLAC)-controlled, crossover trial, 45 patients with nondiabetic CKD stages

66 In a randomized, crossover trial, 48 children with CF were allocated cons

67 In this single-blinded crossover trial, 50 patients with RA were randomly assig

68 rate 4-wk, placebo-controlled, double-blind, crossover trials, 50 healthy adults with low dietary fib

69 In this double-blind, randomized crossover trial, 51 women (n = 32 breast cancer survivor

70 In a randomized crossover trial, 55 healthy Danish 8- to 13-y-olds recei

71 ntrolled, double-blind, randomized, 3-period crossover trial (8 wk of treatment, 6 wk of washout) tha

72 In a double-blind crossover trial, 80 patients with rheumatoid arthritis (

73 In an open randomized crossover trial, 98 patients with coronary heart disease

74 In a randomized crossover trial, a diet containing 300 g shrimp/d, which

75 ANTS: This was a 9-month randomized clinical crossover trial (AB-BA) with a 2- to 4-week washout peri

76 ind, randomized, placebo-controlled clinical crossover trial, acetyl-DL-leucine in the investigated d

77 blind, randomized, placebo-controlled, 3-way crossover trial after nonembolic cerebrovascular events

78 and 40% oxygen/60% nitrogen in a randomized crossover trial, again controlling for tidal volume.

79 This was a cluster-randomized, multiple-crossover trial among 974 adults admitted to a tertiary

80 REACH was a randomised, open-label, phase 2a crossover trial among HIV-seronegative, non-pregnant ado

81 As all studies were crossover trials, an inverse variance statistical method

82 ble blind, placebo-controlled NIMH inpatient crossover trial and examined for association with risk f

83 .90, a sample size of 24 is required for the crossover trial and over 150 subjects for the parallel d

84 als in type 2 diabetes (TriMaster three-drug crossover trial and two parallel-arm trials [NCT00622284

85 e quality of reporting in cluster randomised crossover trials and relevant CONSORT statements for ind

86 male volunteers were randomly assigned in a crossover trial, and after a washout period, all subject

87 Studies 1 and 2 were randomized controlled crossover trials, and study 3 was a parallel study.

88 le-blind, placebo-controlled, single-centre, crossover trial assessed the effectiveness of an oral ne

89 randomized, double-blind, placebo-controlled crossover trial assessing a TRPV1 antagonist (SB-705498)

90 a double-blind placebo-controlled randomized crossover trial assessing the effects of high versus low

91 Randomized, double-blinded, crossover trial assessing the effects of overnight suppl

92 Double-masked, randomized crossover trial at 13 study sites, including the Peli la

93 In a randomized, crossover trial at 2 centers, 51 healthy participants (a

94 In a cluster-randomized, crossover trial at 25 hospitals in the United States and

95 We did a pragmatic, cluster-randomised, crossover trial at nine hospitals in the southeastern US

96 randomised, double-blind, placebo-controlled crossover trial at ten centres in Canada, the Czech Repu

97 sed controlled, non-inferiority, four-period crossover trial at three sites in Shanghai, China, and o

98 : We conducted a cluster-randomized, cluster-crossover trial between July 2019 and August 2020 in two

99 In a double-blind, placebo-controlled crossover trial, challenges involving two food color add

100 andomized, placebo-controlled, double-blind, crossover trial comparing 1 night of 80 mg atomoxetine p

101 Pragmatic, cluster randomized crossover trial comparing 12 months of SOD with 12 month

102 rom healthy adults enrolled in a randomized, crossover trial comparing a high-PA diet to a low-PA/hig

103 double-blind, placebo-controlled, randomized crossover trial comparing albuterol inhalation aerosol w

104 e conducted a 6-week, randomized, open-label crossover trial comparing amiloride/hydrochlorothiazide

105 a pivotal Phase 3, randomized, double-blind, crossover trial comparing ammonia control, assessed as 2

106 We conducted a double-blind crossover trial comparing gabapentin (up to 900 mg/day)

107 were evaluated in a prospective, randomized, crossover trial comparing hypoxia (17% FIO(2)) with hype

108 Proof-of-concept, randomized, double-blind, crossover trial comparing ketamine with an active placeb

109 one preterm infants enrolled in a randomized crossover trial comparing nHFOV with nasal continuous po

110 A quasi-experimental, crossover trial comparing PPA and PPRF for adult inpatie

111 ecord-embedded, cluster-randomized, multiple-crossover trial comparing saline with balanced crystallo

112 , controlled, double-blinded, interventional crossover trial comparing standard terminal cleaning fol

113 conducted a multicenter, cluster-randomized, crossover trial comparing two schedules for pediatric re

114 The study was a randomized crossover trial, comparing intervention (0.5-1.0 micro T

115 tudy was a double-blind, placebo-controlled, crossover trial conducted in children and young adults a

116 In a pragmatic, cluster-randomized, cluster-crossover trial conducted in the emergency department an

117 Patients in the crossover trial continued to receive divalproex sodium.

118 ted using a double-blind, placebo-controlled crossover trial, counterbalanced for order.

119 MIP-1072 and (123)I-MIP-1095 2 wk apart in a crossover trial design.

120 were obtained from a randomized, controlled, crossover trial designed to characterize the metabolic r

121 We conducted a double-blind, randomized, crossover trial designed to detect a small effect of tre

122 In a randomized crossover trial (DRKS00017686) with 24 young adults (12

123 es of separate single-blind, Sham-controlled crossover trials, each including 24 healthy older adults

124 The present randomized controlled crossover trial enrolled adults with objectively verifie

125 Of these, five crossover trials, enrolling a total of 71 patients (63 a

126 ecent small double-blind, placebo-controlled crossover trial (EudraCT no.

127 andomized, double-blind, placebo-controlled, crossover trial evaluating the pharmacodynamic effects o

128 a phase 3, placebo-controlled, double-blind crossover trial evaluating whether ubrogepant 100 mg, a

129 domized, placebo-controlled, double-blinded, crossover trial examined well-controlled T2D patients re

130 In a randomized crossover trial, fasting plasma samples were obtained fr

131 A randomized, double-blind crossover trial for two successive painful procedures (b

132 A phase 2 randomized, placebo-controlled, crossover trial found that the GABA-B agonist arbaclofen

133 In this multinational, randomised, crossover trial (Fuzzy Logic Automated Insulin Regulatio

134 , double-blind, placebo-controlled, 3-period crossover trial, healthy adult men (n = 21) consumed bar

135 ouble-blind, placebo-controlled, two-period, crossover trial in 11 allergic asthmatic patients.

136 double-blind, placebo-controlled, two-period crossover trial in 12 subjects with mild-to-moderate ast

137 We performed a randomized, 3-way crossover trial in 14 healthy volunteers who ingested 7.

138 double-blind, randomized, placebo-controlled crossover trial in 18 adults with DSM-5 SAD and compared

139 We performed a random-order, double-blind, crossover trial in 20 patients with exercise-induced ast

140 andomized, double-blind, placebo-controlled, crossover trial in 223 healthy men and women aged 18-70

141 We conducted a randomized, double-blind, crossover trial in 24 postmenopausal women, each of whom

142 We did a pragmatic cluster-randomised crossover trial in 29 UK pharmacies among women receivin

143 andomized, double-blind, placebo-controlled, crossover trial in 75 men and women with coronary artery

144 A randomized crossover trial in 9 healthy ileostomy participants was

145 Methods: First, an interventional crossover trial in adult subjects with ARDS and BMI >=35

146 This was a 3-period randomized crossover trial in free-living healthy individuals who c

147 A randomized crossover trial in males with 4 d + 4 d of LC and HC, re

148 IPANTS: A randomized, double-blind, repeated crossover trial in men and women with grade 1 hypertensi

149 Acute effects were assessed in a crossover trial in normal subjects (single dose of 25 mg

150 double-blind, randomised, placebo-controlled crossover trial in patients aged 18-65 years with modera

151 was a multicentre, randomised, double-blind, crossover trial in patients with DPNP with mean daily pa

152 This was a randomized crossover trial in pregnant women (26-28 wk of gestation

153 This randomized crossover trial in Quetzaltenango, Guatemala included 26

154 ouble-blind, randomised, placebo-controlled, crossover trial in two UK medical centres.

155 We designed a crossover trial in which 24 men, 23 premenopausal women,

156 ts initially entered a 24-week, double-blind crossover trial in which fluphenazine and placebo were a

157 n study 3, an open-label, placebo-controlled crossover trial, in 12 men with mild-to-moderate COPD.

158 Our original study was a crossover trial including 19 otherwise healthy smokers w

159 8.2 years, mean +/- SD) completed a 16-week crossover trial including 2-week baseline recording, 6 w

160 andomized, double-blind, placebo-controlled, crossover trial including 20 high-functional adult males

161 IPANTS: In a randomized, within-participant, crossover trial including 3 separate visits, participant

162 Randomized, double-blind, treat-to-target crossover trial including two 32-week treatment periods,

163 participated in a randomized, double-blind, crossover trial, including two 6-8 days treatment period

164 The results of this randomized crossover trial indicate that pregabalin significantly r

165 In this crossover trial, individual UACR responses to dapagliflo

166 A cluster randomised crossover trial involves randomisation of groups of indi

167 In a three-way, double-blind, triple-dummy crossover trial involving 210 patients with asthma, we e

168 The second study was a crossover trial involving 22 subjects with hereditary an

169 andomized, placebo-controlled, double-blind, crossover trial involving 51 patients with OSA living be

170 Nonrandomized crossover trial involving 6 healthy adults who were trea

171 In a randomized crossover trial (ISRCTN11327221; isrctn.com), we investi

172 In this phase II randomised crossover trial, low-dose fish oil was effective in redu

173 10-wk randomized, controlled, double-blind, crossover trial (mean age 51.1 y; mean fasting plasma gl

174 In this randomized crossover trial, miscuffing resulted in strikingly inacc

175 subjects who entered the placebo-controlled crossover trial, mixed amphetamine salts was significant

176 This 3-leg crossover trial (n = 14) investigated the effects of the

177 ) double-blind, placebo-controlled inpatient crossover trial (N=54) and the multicenter outpatient Cl

178 e randomized double-blind placebo-controlled crossover trial of 14 female patients (median age 52 [30

179 UK-based randomized, double-blind, three-way crossover trial of 16 weeks of treatment with each of si

180 OmniHeart is a randomized crossover trial of 164 men and women (>=30 y old); 163 p

181 els of hs-CRP in a randomized, double-blind, crossover trial of 22 patients with combined hyperlipide

182 ty-three adults participated in a randomized crossover trial of 3 controlled feeding phases of 25 d e

183 A randomized crossover trial of 3 interventions, including a day of f

184 andomized, double-blind, placebo-controlled, crossover trial of 3 QT-prolonging drugs with 15 time-ma

185 randomized, double-blind, placebo-controlled crossover trial of 6 weeks intranasal administrations of

186 Therefore, we performed a randomized crossover trial of 8 weeks of CPAP and 8 weeks of MRS tr

187 andomised, placebo-controlled, double-blind, crossover trial of a quadpill-a single capsule containin

188 ndertook a double-blind, placebo-controlled, crossover trial of acute tryptophan depletion using func

189 We conducted a pragmatic, two-armed, cluster-crossover trial of adults undergoing extubation from inv

190 In this randomized crossover trial of autistic children, using SADE was saf

191 athy) is a multicenter, blinded, randomized, crossover trial of AVD-optimized RVP in patients with sy

192 , and Activity Monitoring (DREAM) randomized crossover trial of children who underwent alternating we

193 andomized, placebo-controlled, double-blind, crossover trial of clarithromycin 500mg with breakfast a

194 , SETTING, AND PARTICIPANTS: This randomized crossover trial of community-dwelling adults with a wide

195 Device Infection Trial) was a large cluster crossover trial of conventional versus incremental antib

196 a double-blind placebo-controlled randomized crossover trial of folic acid at 5 mg/m2 in 25 normotens

197 We did a randomised crossover trial of glicazide and metformin in 36 patient

198 a previous double-blind, placebo-controlled, crossover trial of healthy volunteers (HVs) unmedicated

199 213 study is the first randomised controlled crossover trial of ileal bile acid transporter inhibitor

200 ntext of a double-blind, placebo-controlled, crossover trial of ketamine in 33 individuals with treat

201 e performed a phase II randomised controlled crossover trial of low-dose and high-dose fish oil in pa

202 andomized, placebo-controlled, double-blind, crossover trial of oral glucosamine at standard doses (5

203 PARTICIPANTS: A randomized, double-blinded, crossover trial of oral pregabalin (50-300 mg/d) vs plac

204 erve tissue.Methods: Randomized double-blind crossover trial of patients with lung cancer and bothers

205 andomized, double-blind, placebo-controlled, crossover trial of patients with type 2 diabetes and hea

206 a 10-week, double-blind, placebo-controlled crossover trial of prasugrel.

207 A double-blind randomized placebo-controlled crossover trial of propranolol in patients with mild-to-

208 In this prospective randomized crossover trial of systemic chemotherapy in patients wit

209 blinded randomized controlled within-subject crossover trial of tight (80-110 mg/dL) vs. loose (120-1

210 double-blind, placebo-controlled, sequential crossover trial of zibotentan (10 mg daily for 12 weeks)

211 criteria: randomized, blinded, parallel, or crossover trials of 5HT(4) agonists, D(2) receptor antag

212 randomized, double-blind, placebo-controlled crossover trials, one involving 42 subjects with hypokal

213 ouble-blind, randomised, placebo-controlled, crossover trial, participants received oral CBD 1000 mg

214 controlled, two-sequence, two-period (2 x 2) crossover trial; participants were randomly assigned (1:

215 riMaster, randomized double-blind, three-way crossover trial patients received three different second

216 In a randomized crossover trial, patients with type 1 diabetes and norma

217 In a double-blind, randomized, crossover trial, people consumed 3 diets, representative

218 d by 3 independent reviewers from randomized crossover trials (RCTs) that investigated the effect of

219 ouble-blind, randomised, placebo-controlled, crossover trial (ReBUILD) in patients with relapsing mul

220 AND PARTICIPANTS: This open-label randomized crossover trial recruited patients at a single tertiary

221 Unknown generalizability to uncontrolled or crossover trial results.

222 a randomized double-blind placebo-controlled crossover trial, SC-51 was administered as a single oral

223 andomized, double-blind, placebo-controlled, crossover trial (September 2004-March 2007) involving 30

224 ensitivity analyses according to presence of crossover, trial size, and dacarbazine dose.

225 an unmasked, cluster-randomised, two-period crossover trial, ten paediatric intensive-care units at

226 TS: Single-center, double-blind, randomized, crossover trial testing the effects of rate-adaptive atr

227 ouble-blind, placebo-controlled, randomized, crossover trial that compared a transdermal patch of ABT

228 randomized, double-blind, placebo-controlled crossover trial that investigated the safety and toxicit

229 ing Healthcare trial is a cluster randomized crossover trial that was conducted in 8 wards with multi

230 olled in separate randomized, double-masked, crossover trials that compared a 3-wk high-palmitic acid

231 In study 4, a placebo-controlled crossover trial, the effect of RPL554 (0.018 mg/kg) on l

232 We examined, in a four-period crossover trial, the influence of metformin (2,000 mg/da

233 We did a randomised controlled crossover trial to compare the efficacy of active OIT (u

234 randomized, double-blind, placebo-controlled crossover trial to determine if mixed amphetamine salts

235 multicenter, cluster-randomized, nonblinded crossover trial to evaluate the effect of daily bathing

236 lemia were enrolled in a placebo-controlled, crossover trial to evaluate the effect of transdermal es

237 , double-blind, placebo-controlled, phase 3, crossover trial to evaluate the efficacy and safety of i

238 ence, we performed a randomized, open-label, crossover trial to examine the effects of NBIW bathing o

239 randomized, double-blind, placebo-controlled crossover trial to investigate the effect of atorvastati

240 We conducted a double-blind, randomized, crossover trial to investigate the efficacy of midodrine

241 mized in a double-blind, placebo-controlled, crossover trial to receive incremental 90-minute infusio

242 domised, double-blinded, placebo-controlled, crossover trial to test whether intake of artificial foo

243 We conducted an open-label crossover trial to test whether proton pump inhibitors (

244 Our randomized, controlled, crossover trial took place at 4 mosques randomized to an

245 ses showed significant improvement in EF for crossover trials, trials with treatment duration </=12 w

246 randomized, double-blind, placebo-controlled crossover trial using an n-of-1 approach was conducted u

247 e studied by home-polygraphy in a randomized crossover trial using either midline-traction with restr

248 randomized, double-blind, placebo-controlled crossover trial using enalapril (0.2 to 0.3 mg x kg[-1]

249 To pilot a cluster-randomized, multiple-crossover trial using software tools within the electron

250 A pilot double-blind, placebo-controlled crossover trial was conducted (ClinicalTrials.gov, NCT02

251 CIPANTS: This cluster randomized, unbalanced crossover trial was conducted at 15 community EDs in nor

252 , SETTING, AND PARTICIPANTS: This randomized crossover trial was conducted at a pediatric dentistry c

253 : This multicenter randomized double-blinded crossover trial was conducted at the University of Penns

254 TING, AND PARTICIPANTS: A cluster-randomized crossover trial was conducted between November 18, 2015,

255 longer-term outcomes of a cluster-randomized crossover trial was conducted from January 9, 2021, to S

256 ICIPANTS: This randomized within-participant crossover trial was conducted from June 3 to June 28, 20

257 andomized, double-blind, placebo-controlled, crossover trial was conducted from November 7, 2017, to

258 D PARTICIPANTS: This single-blind randomized crossover trial was conducted from September 2020 to Oct

259 ING, AND PARTICIPANTS: This pilot randomized crossover trial was conducted from September to November

260 andomized, double-blind, placebo-controlled, crossover trial was conducted in 19 young, healthy, nons

261 A randomized crossover trial was conducted in 22 young, healthy, norm

262 A 2-period pragmatic cluster randomized crossover trial was conducted.

263 This open-label, cluster, crossover trial was done in two Ghanaian non-tertiary ho

264 A single blind randomized crossover trial was performed comparing placebo (PL); lo

265 A randomized, double-blind crossover trial was performed in 6 malabsorptive patient

266 In a double-blind, randomized, crossover trial we sought to evaluate the effect of dual

267 a double-blind randomized placebo-controlled crossover trial, we administered a mild inflammatory sti

268 In a randomized, placebo-controlled, crossover trial, we administered testosterone cypionate

269 this multicenter, multinational, randomized, crossover trial, we assessed the short-term safety and e

270 In this 42-week, double-blind, crossover trial, we assigned 295 patients who were at le

271 quence, cross-sectional, cluster-randomized, crossover trial, we assigned hospitals in Ontario, Canad

272 andomized, double-blind, placebo-controlled, crossover trial, we compared 4-week treatment with empag

273 In this randomized crossover trial, we compared the effects of 1 month each

274 d, single-center, quadruple-masked phase III crossover trial, we compared the total infection severit

275 inded, balanced, randomized, sham-controlled crossover trial, we determined the effect of a single-se

276 In this double-blind, placebo-controlled, crossover trial, we enrolled patients aged 18-79 years w

277 In this pragmatic cluster randomised crossover trial, we enrolled women (aged >=16 years) att

278 In this randomized controlled crossover trial, we investigated the effects of intranas

279 In a randomized controlled crossover trial, we investigated whether the cardiac res

280 In this phase 3, double-blind, three-way crossover trial, we randomly assigned participants at le

281 In this double-blind, placebo-controlled, crossover trial, we randomly assigned patients 4 years o

282 In this multicenter, randomized, crossover trial, we recruited children 1 to 7 years of a

283 In a randomised, double-blind, crossover trial, we recruited eligible patients (severe

284 In this randomised, controlled, crossover trial, we recruited healthy volunteers (aged 2

285 In a randomised crossover trial, we screened 218 patients with chronic f

286 ind, placebo-controlled, randomized, two-way crossover trials were undertaken.

287 conducted a placebo-controlled, randomized, crossover trial where, after a 1 week baseline period, p

288 onducted a placebo-controlled, double-blind, crossover trial with 10 healthy participants.

289 lled-feeding study conducted as a randomized crossover trial with 2 treatment phases.

290 We conducted a randomized, double-blind crossover trial with 3 intervention phases among 352 adu

291 weekly or placebo in a double-blind, partial-crossover trial with a second random assignment at year

292 domized, double-blinded, placebo-controlled, crossover trial with ivabradine.

293 natives Trial) was a single-site, randomized crossover trial with no washout period.

294 In a cluster-randomized, crossover trial with strategies rotated in 4-month perio

295 a double-blind randomized placebo-controlled crossover trial with three protocols each consisting of

296 andomized, double-blind, placebo-controlled, crossover trial with three study periods.

297 -40 y of age) were recruited in a randomized crossover trial with two 14-d isoenergetic diet periods

298 andomized, double-blind, placebo-controlled, crossover trial with two treatment periods each of two w

299 s included double-blind, placebo-controlled, crossover trials with beta blocker drugs and a phosphodi

300 Crossover trials with less than 2 weeks' washout between